February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

Genetics Providing New Insights into Signaling Pathways and Treatment Targets in ALL

Rituximab Maintenance and Radioimmunotherapy Are Cost-Effective After First-Line Therapy in Follicular Lymphoma

Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money

Idelalisib Improves Outcomes in Heavily Pretreated Patients with CLL

Gazyva for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology

Lisa A. Raedler, PhD, RPh

Conference Highlights ASH

Siltuximab: Monoclonal Antibody Relieves Symptoms of Castleman’s Disease

Conference Highlights ASH

More Transplants Made Possible Through Haploidentical Donors

Caroline Helwick

Conference Highlights ASH

Hospital Readmission After Stem-Cell Transplant Decreases Survival

Conference Highlights ASH

JAK1/2 Inhibitor Ruxolitinib Improves Survival in High-Risk Myelofibrosis

Payers' Perspectives

Increasing Emphasis on Costs in the Management of Patients with Hematologic Cancers

Matthew Mitchell, PharmD, MBA, FAMCP

1
2
3
4

Page 1 of 4
Results 1 - 10 of 32

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.